{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:23:02Z","timestamp":1765610582656,"version":"3.44.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,28]]},"DOI":"10.7759\/cureus.93442","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T03:57:27Z","timestamp":1759118247000},"source":"Crossref","is-referenced-by-count":1,"title":["Ileostomy for Refractory Immune Checkpoint Inhibitor-Associated Colitis: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Koji","family":"Daito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Haeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issei","family":"Umeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junnichiro","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja L","year":"2017","unstructured":"Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017, 28:2377-85. 10.1093\/annonc\/mdx286","journal-title":"Ann Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0047","article-title":"New NCCN guidelines: recognition and management of immunotherapy-related toxicity","volume":"16","author":"Thompson JA","year":"2018","unstructured":"Thompson JA. New NCCN guidelines: recognition and management of immunotherapy-related toxicity. J Natl Compr Canc Netw. 2018, 16:594-6. 10.6004\/jnccn.2018.0047","journal-title":"J Natl Compr Canc Netw"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05707-3","article-title":"Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors","volume":"28","author":"Dougan M","year":"2020","unstructured":"Dougan M, Blidner AG, Choi J, et al.. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. Support Care Cancer. 2020, 28:6129-43. 10.1007\/s00520-020-05707-3","journal-title":"Support Care Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.298.6666.82","article-title":"Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial","volume":"298","author":"Rachmilewitz D","year":"1989","unstructured":"Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989, 298:82-6. 10.1136\/bmj.298.6666.82","journal-title":"BMJ"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer EA","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al.. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009, 45:228-47. 10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.1182","article-title":"Ipilimumab as a cause of severe pan-colitis and colonic perforation","volume":"9","author":"Shah R","year":"2017","unstructured":"Shah R, Witt D, Asif T, Mir FF. Ipilimumab as a cause of severe pan-colitis and colonic perforation. Cureus. 2017, 9:e1182. 10.7759\/cureus.1182","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2478\/pjs-2014-0017","article-title":"Multiple colon perforation as a fatal complication during treatment of metastatic melanoma with ipilimumab - case report","volume":"86","author":"Dilling P","year":"2014","unstructured":"Dilling P, Walczak J, Pikiel P, Kruszewski WJ. Multiple colon perforation as a fatal complication during treatment of metastatic melanoma with ipilimumab - case report. Pol Przegl Chir. 2014, 86:94-6. 10.2478\/pjs-2014-0017","journal-title":"Pol Przegl Chir"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2019.1580477","article-title":"A case of nivolumab-associated colitis, which relapsed after mucosal healing and was then successfully treated with mesalazine","volume":"42","author":"Kikuchi H","year":"2019","unstructured":"Kikuchi H, Sakuraba H, Akemoto Y, et al.. A case of nivolumab-associated colitis, which relapsed after mucosal healing and was then successfully treated with mesalazine. Immunol Med. 2019, 42:39-44. 10.1080\/25785826.2019.1580477","journal-title":"Immunol Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2463","article-title":"Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc\/IV melanoma","volume":"17","author":"Sarnaik AA","year":"2011","unstructured":"Sarnaik AA, Yu B, Yu D, et al.. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc\/IV melanoma. Clin Cancer Res. 2011, 17:896-906. 10.1158\/1078-0432.CCR-10-2463","journal-title":"Clin Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen JB","year":"2017","unstructured":"Haanen JB, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017, 28:iv119-42. 10.1093\/annonc\/mdx225","journal-title":"Ann Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000309","article-title":"Complete recovery of immune checkpoint inhibitor-induced colitis by diverting loop ileostomy","volume":"43","author":"Horisberger K","year":"2020","unstructured":"Horisberger K, Portenkirchner C, Rickenbacher A, Biedermann L, Gubler C, Turina M. Complete recovery of immune checkpoint inhibitor-induced colitis by diverting loop ileostomy. J Immunother. 2020, 43:145-8. 10.1097\/CJI.0000000000000309","journal-title":"J Immunother"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille C","year":"2020","unstructured":"Dolladille C, Ederhy S, Sassier M, et al.. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 2020, 6:865-71. 10.1001\/jamaoncol.2020.0726","journal-title":"JAMA Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00320","article-title":"Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis","volume":"37","author":"Abu-Sbeih H","year":"2019","unstructured":"Abu-Sbeih H, Ali FS, Naqash AR, et al.. Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis. J Clin Oncol. 2019, 37:2738-45. 10.1200\/JCO.19.00320","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer","volume":"5","author":"Simonaggio A","year":"2019","unstructured":"Simonaggio A, Michot JM, Voisin AL, et al.. Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol. 2019, 5:1310-7. 10.1001\/jamaoncol.2019.1022","journal-title":"JAMA Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9610(71)90252-2","article-title":"Surgical treatment of toxic megacolon. Ileostomy and colostomy to prepare patients for colectomy","volume":"122","author":"Turnbull RB Jr","year":"1971","unstructured":"Turnbull RB Jr, Hawk WA, Weakley FL. Surgical treatment of toxic megacolon. Ileostomy and colostomy to prepare patients for colectomy. Am J Surg. 1971, 122:325-31. 10.1016\/0002-9610(71)90252-2","journal-title":"Am J Surg"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/codi.13413","article-title":"Surgical management of complicated and medically refractory inflammatory bowel disease during pregnancy","volume":"19","author":"Killeen S","year":"2017","unstructured":"Killeen S, Gunn J, Hartley J. Surgical management of complicated and medically refractory inflammatory bowel disease during pregnancy. Colorectal Dis. 2017, 19:123-38. 10.1111\/codi.13413","journal-title":"Colorectal Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s10350-004-6504-6","article-title":"Turnbull-Blowhole colostomy for toxic ulcerative colitis in pregnancy: report of two cases","volume":"46","author":"Ooi BS","year":"2003","unstructured":"Ooi BS, Remzi FH, Fazio VW. Turnbull-Blowhole colostomy for toxic ulcerative colitis in pregnancy: report of two cases. Dis Colon Rectum. 2003, 46:111-5. 10.1007\/s10350-004-6504-6","journal-title":"Dis Colon Rectum"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/344752-ileostomy-for-refractory-immune-checkpoint-inhibitor-associated-colitis-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T03:57:30Z","timestamp":1759118250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/344752-ileostomy-for-refractory-immune-checkpoint-inhibitor-associated-colitis-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,28]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.93442","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,28]]}}}